Autoradiographic characterisation of [35S]GTP gamma S binding sites in rat brain

Neurotransmitter receptor localization: from autoradiography to imaging mass spectrometry

Autoradiography is used to determine the anatomical distribution of biological molecules in human tissue and experimental animal models. This method is based on the analysis of the specific binding of radiolabeled compounds to locate neurotransmitter receptors or transporters in fresh frozen tissue slices. The anatomical resolution obtained by quantification of the radioligands has allowed the density of receptor proteins to be mapped over the last 40 years. The data yielded by autoradiography identify the receptors at their specific microscopic localization in the tissues and also in their native microenvironment, the intact cell membrane. Furthermore, in functional autoradiography, the effects of small molecules on the activity of G protein-coupled receptors are evaluated. More recently, autoradiography has been combined with membrane microarrays to improve the high-throughput screening of compounds. These technical advances have made autoradiography an essential analytical method for the progress of drug discovery. We include the future prospects and some preliminary results for imaging mass spectrometry (IMS) as a useful new method in pharmacodynamic and pharmacokinetic studies, complementing autoradiographic studies. IMS results could also be presented as density maps of molecules, proteins, and metabolites in tissue sections that can be identified, localized, and quantified, with the advantage of avoiding any labeling of marker molecules. The limitations and future developments of these techniques are discussed here.

Loss of stimulatory effect of guanosine triphosphate on [(35)S]GTPgammaS binding correlates with Alzheimer's disease neurofibrillary pathology in entorhinal cortex and CA1 hippocampal subfield

Heterotrimeric guanosine triphosphate (GTP)-binding proteins (G-proteins) couple many different cell surface receptor types to intracellular effector mechanisms. Uncoupling between receptors and G-proteins and between G-proteins and adenylyl cyclase (AC) and phospholipase C (PLC) has been described for Alzheimer's disease (AD) brain. However, there is little information on whether altered G-protein signaling in AD is just an end-stage phenomenon or is important for the progression of disease pathology. Here we used [(35)S]GTPgammaS autoradiography to study G-protein distribution in sections of entorhinal cortex and hippocampus from 23 cases staged for neurofibrillary changes and amyloid deposits according to Braak and Braak (Acta Neuropathol. [1991] 82:239-259). We also studied the effects of GTP, which has been found to increase [(35)S]GTPgammaS binding in an Mg(2+)-dependent manner. Results show that the ability of GTP (3 microM) to stimulate [(35)S]GTPgammaS binding declined significantly with staging for neurofibrillary changes in the entorhinal cortex (P < 0.05, ANOVA) and CA1 subfield of the hippocampus (P < 0.05, ANOVA). No significant changes were seen for [(35)S]GTPgammaS binding in the absence of GTP. Our results suggest a decrease in G-protein GTP hydrolysis, which correlates with the progression of AD neurofibrillary changes, in the regions most affected by this pathology. These alterations appear to occur prior to stages corresponding to clinical disease and could lead to an impaired regulation of several signaling systems in AD brain.

A GppNHp-insensitivity factor modulates the activation of beta-adrenoceptor-coupled Gs protein in rat cortex and cerebellum

The effect known as the GTP-shift refers to the complete conversion of receptors from the high- to the low agonist-affinity state in the presence of an excess of GTP or one of its analogs. 5'-Guanylylimidodiphosphate (GppNHp) was able to fully suppress the high (-)-isoproterenol-affinity of beta-adrenoceptors (beta AR) in cultured rat brain astrocytes. In contrast, a proportion of beta AR in rat cortex and cerebellum synaptosomes was found to be insensitive to this GTP analog. This GppNHp-insensitivity was due to a membrane-associated factor, presumably interacting with Gs proteins and not present in a functional form in cultured astrocytes. Here we assessed the effect of this factor on the beta AR-mediated activation of Gs proteins. The removal of the GppNHp-insensitivity factor from the synaptosomes was achieved using 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), a mild detergent. The activation of Gs proteins was monitored by the binding of another non-hydrolysable GTP-analog, guanylyl 5'-[gamma-[35S]thio]-triphosphate ([35S]GTP gamma S). The beta AR-Gs protein coupling was at least twofold less efficient in synaptosomes relative to cultured astrocytes. The CHAPS treatment induced a twofold increase in the coupling efficiency in cortex and cerebellum synaptosomes, but had no effect in cultured astrocytes. It undoubtedly indicated the inhibitory effect of the GppNHp-insensitivity factor on the activation of Gs proteins in the synaptosomes. Using CHAPS-soluble material extracted from synaptosomes, it was possible to reconstitute the GppNHp-insensitivity of CHAPS-treated membranes or even to induce it in cultured astrocytes. This effect correlated with the amount of CHAPS-soluble material according to a sigmoid curve, but it was abolished by the heat of CHAPS-soluble material. Successful crossed reconstitutions of the GppNHp-insensitivity suggest that the GppNHp-insensitivity factor is the same regardless of its originating area, and that it might play a general role in the central nervous system. Further investigations should help to identify the GppNHp-insensitivity factor.